| Terminated | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With U Mesothelioma, Malignant | Phase 2 | 2015-11-03 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | 2013-11-01 |
| Completed | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancrea Breast Cancer, Pancreatic Cancer, Colorectal Cancer | Phase 1 | 2013-06-19 |
| Completed | Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects Rheumatoid Arthritis | Phase 1 | 2013-05-01 |
| Completed | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation Metastatic Soft Tissue Sarcoma | Phase 2 | 2012-08-07 |
| Terminated | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) Metastatic Colorectal Cancer, Colorectal Cancer | Phase 2 | 2012-03-27 |
| Completed | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Mesothelioma, Pancreatic Cancer, Ovarian Cancer | Phase 1 | 2011-09-01 |
| Completed | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung Adenocarcinoma of the Lung | Phase 2 | 2011-06-27 |
| Withdrawn | Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Resectable, Non-functioning Pituitary Adenoma | Phase 2 | 2011-02-01 |
| Terminated | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma | Phase 1 | 2010-12-01 |
| Terminated | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma Melanoma | Phase 1 | 2010-05-01 |
| Terminated | An Open Label Extension Study of the Efficacy of MORAb-003 Epithelial Ovarian Cancer | Phase 2 | 2010-01-13 |
| Completed | Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitiv Epithelial Ovarian Cancer | Phase 1 | 2009-11-01 |
| Terminated | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants Wit Ovarian Cancer | Phase 3 | 2009-04-16 |
| Completed | A Study of of MORAb-004 in Subjects With Solid Tumors Solid Tumor | Phase 1 | 2009-03-01 |
| Completed | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Malignant Pleural Mesothelioma | Phase 2 | 2008-12-31 |
| Terminated | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer Ovarian Cancer | Phase 2 | 2008-09-01 |
| Completed | An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2007-12-01 |
| Completed | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms | Phase 2 | 2006-05-01 |
| Completed | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Can Pancreatic Cancer, Mesothelioma, Ovarian Cancer | Phase 1 | 2006-05-01 |
| Completed | Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer Epithelial Ovarian Cancer | Phase 1 | 2005-06-01 |